Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.78
INCY's Cash to Debt is ranked higher than
55% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. INCY: 0.78 )
INCY' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 0.78

Equity to Asset -0.24
INCY's Equity to Asset is ranked lower than
52% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INCY: -0.24 )
INCY' s 10-Year Equity to Asset Range
Min: -1.83   Max: 0.92
Current: -0.24

-1.83
0.92
F-Score: 4
Z-Score: 2.67
M-Score: -1.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.54
INCY's Operating margin (%) is ranked higher than
80% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. INCY: -4.54 )
INCY' s 10-Year Operating margin (%) Range
Min: -4064.53   Max: 9.05
Current: -4.54

-4064.53
9.05
Net-margin (%) -23.43
INCY's Net-margin (%) is ranked higher than
75% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. INCY: -23.43 )
INCY' s 10-Year Net-margin (%) Range
Min: -4565.45   Max: 7.67
Current: -23.43

-4565.45
7.67
ROA (%) -13.21
INCY's ROA (%) is ranked higher than
74% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. INCY: -13.21 )
INCY' s 10-Year ROA (%) Range
Min: -76.99   Max: 3.47
Current: -13.21

-76.99
3.47
ROC (Joel Greenblatt) (%) -59.97
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. INCY: -59.97 )
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5697.03   Max: 292.44
Current: -59.97

-5697.03
292.44
Revenue Growth (%) 19.50
INCY's Revenue Growth (%) is ranked higher than
89% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. INCY: 19.50 )
INCY' s 10-Year Revenue Growth (%) Range
Min: -61.4   Max: 194.1
Current: 19.5

-61.4
194.1
EPS Growth (%) 29.10
INCY's EPS Growth (%) is ranked higher than
94% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. INCY: 29.10 )
INCY' s 10-Year EPS Growth (%) Range
Min: -45.1   Max: 64.9
Current: 29.1

-45.1
64.9
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

INCY Guru Trades in Q3 2013

Steven Cohen 98,391 sh (New)
Vanguard Health Care Fund 3,807,443 sh (unchged)
Mariko Gordon 162,214 sh (-3.84%)
Manning & Napier Advisors, Inc 209,810 sh (-51.31%)
Jim Simons 44,700 sh (-56.52%)
» More
Q4 2013

INCY Guru Trades in Q4 2013

Paul Tudor Jones 5,423 sh (New)
Vanguard Health Care Fund 4,457,643 sh (+17.08%)
Steven Cohen 107,338 sh (+9.09%)
Jim Simons Sold Out
Manning & Napier Advisors, Inc 202,580 sh (-3.45%)
Mariko Gordon 128,959 sh (-20.5%)
» More
Q1 2014

INCY Guru Trades in Q1 2014

George Soros 23,200 sh (New)
Vanguard Health Care Fund 4,901,968 sh (+9.97%)
Manning & Napier Advisors, Inc Sold Out
Paul Tudor Jones Sold Out
Mariko Gordon 112,623 sh (-12.67%)
Steven Cohen 42,149 sh (-60.73%)
» More
Q2 2014

INCY Guru Trades in Q2 2014

Ken Fisher 12,225 sh (New)
Vanguard Health Care Fund 9,591,143 sh (+95.66%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Add 95.66%0.68%$43.1 - $56.39 $ 47.57-7%9591143
George Soros 2014-03-31 New Buy0.01%$49.94 - $68.83 $ 47.57-23%23200
Mariko Gordon 2013-12-31 Reduce -20.5%0.06%$34.71 - $51.34 $ 47.5710%128959
Vanguard Health Care Fund 2013-06-30 Add 21.52%0.05%$19.07 - $24.49 $ 47.57118%3807443
Vanguard Health Care Fund 2013-03-31 New Buy0.29%$16.61 - $24.95 $ 47.57133%3133100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Incyte Corp Ltd

Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Aramark, Incyte Corp Ltd. and Facebook Inc. Read more...
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN
According to GuruFocus Insider Data, the largest insider sells during the past week were: Aramark, Incyte Corp Ltd, Emeritus Corp, and Huntsman Corp. Read more...
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Pandora Media Inc, Incyte Corp Ltd, Google Inc, and American Airlines Group Inc. Read more...

Ratios

vs
industry
vs
history
P/S 19.88
INCY's P/S is ranked higher than
70% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. INCY: 19.88 )
INCY' s 10-Year P/S Range
Min: 5.51   Max: 209.75
Current: 19.88

5.51
209.75
EV-to-EBIT -228.13
INCY's EV-to-EBIT is ranked higher than
60% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INCY: -228.13 )
INCY' s 10-Year EV-to-EBIT Range
Min: 79.8   Max: 2896.5
Current: -228.13

79.8
2896.5
Current Ratio 5.43
INCY's Current Ratio is ranked higher than
78% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. INCY: 5.43 )
INCY' s 10-Year Current Ratio Range
Min: 1.51   Max: 21.14
Current: 5.43

1.51
21.14
Quick Ratio 5.43
INCY's Quick Ratio is ranked higher than
79% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. INCY: 5.43 )
INCY' s 10-Year Quick Ratio Range
Min: 1.51   Max: 21.14
Current: 5.43

1.51
21.14

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.90
INCY's Price/Median PS Value is ranked higher than
88% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. INCY: 0.90 )
INCY' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 15.77
Current: 0.9

0.11
15.77
Earnings Yield (Greenblatt) 0.30
INCY's Earnings Yield (Greenblatt) is ranked lower than
64% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. INCY: 0.30 )
INCY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 1.3
Current: 0.3

0.3
1.3
Forward Rate of Return (Yacktman) -0.83
INCY's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. INCY: -0.83 )
INCY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.6   Max: -1.3
Current: -0.83

-6.6
-1.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany
Incyte Corp Ltd was incorporated in Delaware in 1991. It is a biopharmaceutical company which discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs. The Company's most advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA) as a treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. MF is a serious, life-threatening blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms that include polycythemia vera and essential thrombocythemia. JAKAFI is the first FDA-approved JAK inhibitor, and is part of a potentially important new oral drug class to treat cancer and chronic inflammatory diseases. The JAK pathway, which consists of four tyrosine kinases—JAK1, JAK2, JAK3 and Tyk2, is dysregulated in many oncologic and inflammatory conditions. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company. The Company's drug discovery and development activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its product candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 


More From Other Websites
Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical... Jul 31 2014
Incyte Corp Earnings Call scheduled for 8:30 am ET today Jul 31 2014
INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 31 2014
Q2 2014 Incyte Corporation Earnings Release - 07:00 am ET Jul 31 2014
Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical... Jul 31 2014
Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer... Jul 30 2014
Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer... Jul 30 2014
Why Incyte (INCY) Might Surprise This Earnings Season Jul 30 2014
Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety... Jul 28 2014
Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety... Jul 28 2014
Incyte's Jakafi Fails to Provide RELIEF in Polycythemia Vera Jul 24 2014
Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia... Jul 23 2014
Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia... Jul 23 2014
Top Biotechnology Stocks Jul 23 2014
AstraZeneca widens cancer immunotherapy net with Advaxis trial Jul 22 2014
Incyte (INCY) Enters Oversold Territory Jul 16 2014
Incyte to Report Second Quarter 2014 Financial Results on July 31 Jul 14 2014
Incyte to Report Second Quarter 2014 Financial Results on July 31 Jul 14 2014
Incyte Earns Milestone Payment on Japanese Approval of Jakavi Jul 09 2014
Incyte Achieves $25 Million Milestone for Approval of Jakavi® (ruxolitinib) in Japan Jul 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide